Capsule Summary Slidesets

Share

Program Content

Activities

  • ATLAS-2M: Wk 48 Results
    ATLAS-2M: Switch to Long-Acting Injectable Cabotegravir + Rilpivirine Every 2 Mos Is Noninferior to Switch to Monthly Injections in Virologically Suppressed Patients at Wk 48
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 10, 2020

  • FLAIR: Week 96 Results
    FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive Patients Noninferior to Continued Oral DTG/ABC/3TC at Wk 96
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 11, 2020

  • Rapid ART in Youth
    Rapid and Sustained Viral Suppression Following Initiation of ART Within 72 Hrs of Diagnosis in Young Persons With HIV in New Orleans
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2020

  • BIC/FTC/TAF in Aging PWH
    BIC/FTC/TAF Efficacy and Safety Similar to DTG-Based 3-Drug Regimens at Wk 144 in ART-Naive Patients Aged 50 Yrs or Older
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2020

  • GEMINI-1 & -2: Wk 96 CVW
    GEMINI-1 and -2: Rates of Confirmed Virologic Withdrawal at Wk 96 Similar With DTG Plus 3TC vs DTG Plus FTC/TDF in Treatment-Naive Patients
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2020

  • ADVANCE: Diabetes and CVD
    ADVANCE: Risk of Cardiovascular Disease and Diabetes in Treatment-Naive Patients Initiating Dolutegravir- or Efavirenz-Based ART
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2020

  • ISL + DOR Metabolic Study
    DRIVE2Simplify Exploratory Analysis: Metabolic Outcomes With Islatravir Plus DOR vs DOR/3TC/TDF in ART-Naive Adults at Wk 48
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2020

  • IMPAACT 2010
    IMPAACT 2010: Viral Suppression Rates at Delivery Significantly Higher With DTG Plus FTC/TAF or FTC/TDF vs EFV/FTC/TDF Initiation During Pregnancy in ART-Naive Women
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2020

  • <i>CYP2B6</i> and Weight on EFV
    ADVANCE Post Hoc Analysis: CYP2B6 Genotype Associated With Differential Weight Gain in ART-Naive Patients Initiating Efavirenz-Based ART in South Africa
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2020

  • DISCOVER 96-Wks
    DISCOVER: More Favorable Renal and Bone Outcomes With FTC/TAF vs FTC/TDF for HIV PrEP Through 96 Wks
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 15, 2020

Provided by

ProCE Banner

Supporters

Gilead

Merck & Co., Inc.

ViiV Healthcare